Apogee Therapeutics, Inc. 13D

Venrock Healthcare Capital Partners and affiliates exited their entire stake in Apogee Therapeutics via AbbVie’s cash merger at $135.11 per share, with no ongoing activist intentions.

Venrock Healthcare Capital Partners III, L.P. and affiliated reporting persons have amended their Schedule 13D to report that, in connection with AbbVie Inc.’s acquisition of Apogee Therapeutics, Inc. completed on September 3, 2026 at $135.11 per share in cash, they disposed of their entire position—consisting of 1,750,000 voting common shares, 6,743,321 non‑voting common shares, 365,853 pre‑funded warrants, and options exercisable for 80,246 shares—and as a result ceased to beneficially own more than 5% of the company, with no ongoing activist or governance intentions disclosed following the merger and Nasdaq delisting.

Filing Facts

CIK

1974640

Ticker

APGE

Form

13D

Source Type

fda

Accession

0001231919-26-001150

Alert Tier

8